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1. As human-wildlife conﬂicts increase worldwide, novel methods are required for mitigating these conﬂicts.
Fertility control, based on immunocontraceptives, has emerged as an alternative option to lethal methods for
managing wildlife.
2. Immunocontraceptives are vaccines that generate an immune response to key components of an animal's
reproductive system. Some of these vaccines target the gonadotropin-releasing hormone (GnRH) and have been
used successfully as contraceptives for many wildlife species. However, the need to capture animals for treatment
limits the ﬁeld applications of injectable vaccines. The availability of orally delivered immunocontraceptives
would increase the breadth of applications of fertility control for wildlife management.
3. This study explored a new approach to developing an oral immunocontraceptive, exploiting the bioadhesive
and immunologically active properties of killed Mycobacterium avium cell wall fragments (MAF). The MAF was
conjugated to a GnRH recombinant protein called IMX294, used as a GnRH-speciﬁc immunogen.
4. An initial trial using the MAF-IMX294 conjugate provided the ﬁrst evidence that an orally delivered
immunocontraceptive vaccine could generate anti-GnRH antibody titres in laboratory rats.
5. Increasing the dose and frequency of vaccine administered to rats, in a second trial, enhanced the immune
response, eliciting titres that reduced the proportion of females giving birth. This provided the ﬁrst evidence of
the contraceptive effect of an oral anti-GnRH vaccine.
6. Future work is required to further increase the immunogenic effect of the oral vaccine and to establish a
dosing schedule that is effective for practical ﬁeld applications.

1. Introduction
Human-wildlife conﬂicts, often due to overabundant wildlife populations, are increasing worldwide and have traditionally been managed
through culling [1, 2, 3]. Growing antipathy for lethal methods, driven
by concerns about animal welfare, human safety, and environmental
impact constrains options for reducing these conﬂicts [4, 5, 6, 7].
Fertility control is often advocated as an alternative to lethal methods
of wildlife management [8, 9, 10, 11]. Fertility control will generally
achieve population reductions over a longer timescale than culling, as
infertile animals are not removed [11, 12]. However, fertility control has
potential advantages over lethal control. For instance, infertile animals in
the population may contribute to density-dependent feedback, slowing

population recovery [13]. Contraception can be particularly effective in
maintaining lower population numbers after initial reduction by culling
[14, 15, 16, 17]. In addition, fertility control may decrease the transmission of diseases by reducing both the number of new-born susceptible
individuals [18, 19] and animal-to-animal contact during mating [20],
and by minimising social perturbation compared to culling [21].
In the last 20 years, ‘single-shot’ injectable immunocontraceptive
vaccines have been widely tested for use in wildlife management [10,
22]. These vaccines work by eliciting an immune response to proteins or
hormones essential for reproduction such as the gonadotrophin releasing
hormone (GnRH). GnRH is responsible for controlling reproduction in
males and females by stimulating the production of the hormones that
lead to ovulation and spermatogenesis. Suppressing GnRH through the
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Speciﬁc objectives of the studies were:

generation of anti-GnRH antibodies prevents animals from reproducing
[23, 24].
One such injectable GnRH-based immunocontraceptive vaccine,
GonaCon (USDA, Pocatello, ID, USA), has proven effective in many
species [3, 11, 22, 25]. Injectable immunocontraceptives rely on adjuvants containing bacterial components to enhance the longevity of
the immune response to a vaccine [22, 26]. For instance, AdjuVac is
an adjuvant based on killed Mycobacterium avium, a ubiquitous,
non-pathogenic bacterium commonly found in most animal species.
As most individuals have previously encountered this bacterium,
using M. avium within a vaccine is thought to elicit a boosted
response by harnessing an animal's natural exposure levels [27]. Perry
et al. [28] demonstrated that the presence of M. avium in AdjuVac
(National Wildlife Research Center, NWRC, United States), was
essential for the successful contraception of black-tailed deer treated
with GonaCon.
However, the utility of GonaCon and other injectable immunocontraceptives is limited by the need to capture animals for injection. The
availability of oral immunocontraceptives would increase the scope of
fertility control applications in wildlife. The development of oral vaccines
is challenging, compared to parenteral delivery, as demonstrated by the
fact that only a few orally administered vaccines currently exist [29, 30].
Rapid degradation of compounds in the digestive tract and poor
permeation capacity across the intestinal mucosa constrain the effectiveness of oral vaccination [30, 31, 32].
In efforts to enhance immunogenicity against GnRH, and explore
smaller compounds with increased potential for mucosal uptake, recombinant molecules containing GnRH have been developed. Osivax
(formerly Imaxio) has formulated a GnRH recombinant construct called
IMX294, comprising a heptameric protein (50,000 MW) containing seven
copies of GnRH. This unique GnRH immunogen was effective as an
injectable contraceptive in male pigs [33].
In addition to acting as an adjuvant, M. avium is acid resistant and
known to imbed in the ileal region of the small intestine, associated with
the immunologically active area of the Peyer's patch [34]. Thus, incorporating antigens into constructs such as M. avium may enhance mucosal
uptake whilst bypassing the acid environment of the stomach.
Whilst AdjuVac contains whole killed M. avium, the current study
pursued a novel method based on formulating M. avium cell wall fragments (MAF) conjugated to a putative GnRH immunogen (MAF-IMX294)
as a potential GnRH vaccine for mammals [35].

1. To assess the immunological and contraceptive effects in laboratory
rats of MAF-IMX294 formulations delivered via intramuscular, oral,
and nasopharyngeal routes.
2. To establish the effects of dose concentration and frequency of oral
formulations of MAF-IMX294 on the immune responses and fertility
of laboratory rats.
2. Methods
The laboratory rat was used as a model mammalian species for this
study. Nulliparous outbred Wistar strain female rats were sourced from a
registered breeder and weighed between 180 and 200g on arrival. Rats
were housed in wire mesh standard breeding cages, 2–3 animals per
cage, in temperature and humidity-controlled rooms on a 12 h light:12 h
dark cycle and provided with ad libitum water and IPS 5002 pellet diet
(Labdiet-IPS Ltd, London, UK). Animals were given two weeks of acclimatization before being randomly assigned to experimental groups
(Table 1).
Two trials were carried out sequentially and only female rats were
treated with the putative contraceptives. During each trial, blood was
collected from the tail vessel of each rat prior to treatment, and again 45
days after ﬁrst dosing (maximum volume 0.5 ml, using a 23G needle).
For blood sampling, animals were held in restraint tubes or anaesthetised using sevoﬂurane. Depending on experimental group, treated
animals were dosed as follows: while conscious, via oral lavage (OL)
using a round-tipped metal catheter; under anaesthesia, via nasopharyngeal lavage (NP) using a pipette, or via intra-muscular injection (IM)
into the back thigh using a 21G needle. Each rat received 1, 3, or 6
doses (Table 1, see details below). Three weeks after completion of the
last dose, adult Wistar strain males of proven fertility were introduced
into the females’ cages. After a further ten days, males were removed
and females were housed singly. Subsequently produced pups were
removed and counted.
The effectiveness of the treatments undertaken during these trials was
measured by:
1. Quantiﬁcation of serum anti-GnRH antibody titres;
2. Reproductive output, expressed as number of rats giving birth and
litter size.

Table 1. Experimental design used in Trial 1 and Trial 2 to test different formulations, concentrations, frequency of dosing and delivery routes of a novel immunocontraceptive vaccine (MAF-IMX294) on the fertility of laboratory rats. MAF-U ¼ M. avium fragments (ultrasound), MAF-M ¼ M. avium fragments (microﬂuidized).
Trial

Group

N

Formulation

Route

Dose

Dose frequency

1

1

10

MAF-U-IMX294

IM injection

200 μg

3

1

2

10

MAF-U-IMX294

Nasopharyngeal

50 μg

3

1

3

10

MAF-U-IMX294

Oral Lavage

500 μg

3

1

4

10

MAF-M-IMX294

IM injection

200 μg

3

1

5

10

MAF-M-IMX294

Nasopharyngeal

50 μg

3

1

6

10

MAF-M-IMX294

Oral Lavage

500 μg

3

1

7

5

MAF-M

IM injection

200 μg

3

1

8

5

MAF-M

Nasopharyngeal

50 μg

3

1

9

5

MAF-M

Oral Lavage

500 μg

3

1

10

10

GonaCon

IM injection

200 μg

1

2

1

10

MAF-IMX294 Low concentration – Low frequency

Oral Lavage

500 μg

3

2

2

10

MAF-IMX294 High concentration – Low frequency

Oral Lavage

2500 μg

3

2

3

10

MAF-IMX294 High concentration – High frequency

Oral Lavage

2500 μg

6

2

4

10

MAF-IMX294 Low concentration – High frequency

Oral Lavage

500 μg

6

2

5

10

MAF-IMX294

IM injection

200 μg

3

2

6

10

Control (not treated)

-

-

-
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with the exception of a positive control group that received a single injection of GonaCon.

2.1. Trial 1. assessing the immunological and contraceptive effects of two
different MAF-IMX294 formulations delivered via oral and nasopharyngeal
routes in comparison to intramuscular

2.2. Trial 2. establish the contraceptive effectiveness of different orally
delivered doses and frequency of MAF-IMX294

Fragmentation of M. avium whole cells was accomplished using an
ultrasound method (MAF-U), or using a microﬂuidizer (MAF-M). For
microﬂuidisation approximately 8–10 ml of a whole cell suspension of
Mycobacterium avium (0.87 g/ml 0.85% saline) was transferred into
110 ml of phosphate buffered saline, pH 7.2. While stirring the solution, 0.5 mg of ribonuclease A (bovine pancreas, Sigma Chemicals)
and 10 μl of deoxyribonuclease (bovine, Sigma) were added, followed
by 1–2 ml of absolute ethanol. Using a M110L microﬂuidizer (Microﬂuidics, Westwood, MA), the solution was microﬂuidized by passing it
three times through a G110Z reaction chamber in an ice bath at
144790 kPa with a 10 min pause between passes. The resulting total
cell lysate was then centrifuged at 30,000 g for 30 min at 4  C and
resulting M. avium fragment (MAF) pellet collected, weighed, and
stored frozen at -20  C. Subsequent analysis of MAF using a particle
size analyzer (Stabino, Microtrak) yielded a bimodal particle size distribution, with the ﬁrst peak ranging from 0.23μm  .075 μm (all
values are mean  SD) to 0.75μm  0.32 μm, max ¼ 0.421μm  0.15
μm, and the second peak ranging from 1.2μm  0.51 μm–4.01μm  2.5
μm, max ¼ 2.11μm  0.74 μm. The fragments of M. avium produced by
each method were coupled to IMX294, to form the MAF-IMX294
conjugate in phosphate-buffered saline (PBS) solution. IMX294 is a
tubular recombinant protein comprised of seven identical monomers,
with each monomer containing a hybrid complement inhibitor chicken
C4 protein fused with a GnRH peptide [36]. Following expression, the
seven monomers join via cysteine-to-cysteine linkages to form a tubular
heptamer (53 kDa).
The conjugation was achieved using a two-step EDC (1-Ethyl-3-(3dimethylaminopropyl) carbodiimide): N-hydroxysuccinimide ester
coupling method [37]. The conjugation method used links free carboxyl
groups to the primary of amine of lysines. Since both IMX 294 and MAF
contain free lysines, the lysine side chains of IMX294 were capped with
sulfo-N-hydroxy-acetate (SNHSA) to make the resulting conjugation
unidirectional. Approximately 8.7 mg of SNHSA in 0.050 ml ultrapure
water was added to a tube containing 2.84 mg ml1 IMX294 in PBS.
Following a 60 min incubation period, the resulting amine-capped
IMX294 solution was transferred to Zeba desalting columns (7K
MWCO, 5 ml, Thermo Scientiﬁc) and centrifuged at 1000 g for 2 min to
remove excess SNHSA. Resulting eluate was collected, yielding 1 ml of
stabile amine-capped IMX294.
To each 1 ml vial of capped IMX294, 0.4 mg of sulfo-NHS and 0.6 mg
of 1-Ethyl-3-(3-dimethylaminopropyl) carbodiimide (EDC) combined in
0.10 ml PBS was added, followed by a 30 min incubation. The resulting
activated IMX294 was eluted through a Zeba desalting column as previously described, and immediately added to 20 mg MAF in PBS and
reacted for 2 h. The conjugation was quenched by adding 0.025 of a
hydroxylamine solution, then transferred to dialysis cassete (Slide-ALyzer® G2, Thermo Scientiﬁc) and dialyzed overnight. The following
morning, the conjugate solution was removed from the cassette and
stored at 4  C. Chemical conjugation was demonstrated by bioassay in
pilot study in which a conjugate was administered to one group while an
unconjugated mixture was given to a second group. Only the conjugated
material produced an anti-GnRH response.
Using a spectrophotometric assay, MAF lysine content was determined to be  1% of total mass. Given a starting conjugation MAF mass of
20 mg and a lysine to IMX294 ratio of 1:1, the theoretical maximum
conjugate IMX294 content would be about 1.4 μmol. All conjugates and
treatment solutions were prepared at the NWRC.
Six treatment groups of rats were used to test the two formulations of
conjugate (MAF-U-IMX294 and MAF-M-IMX294) compared to negative
controls (MAF-M only) with treatments delivered by intramuscular injection, nasopharyngeal lavage, or oral lavage (Table 1). All groups were
administered a prime dose followed by two boosters at 15 day intervals,

The aim of Trial 2 was to optimise the formulation of the oral vaccine
and thereby increase the potential to reduce rat fertility, by a) increasing
the concentration of MAF-IMX294 from the 1000 μg/ml of solution used
in Trial 1–5000 μg/ml; and b) increasing the frequency of administration
from three to six evenly spaced doses over the same time period of 30
days. Nasopharyngeal delivery groups were not included in Trial 2 as
Trial 1 indicated that similar immune responses could be generated
through oral delivery, which is more practical for ﬁeld use.
Microﬂuidized M. avium fragments (MAF-M) were used in Trial 2, as
no differences were apparent in the anti-GnRH antibodies produced by
the MAF obtained by ultrasound or by microﬂuidization in Trial 1.
Additionally, for IM treatments the MAF-IMX294 conjugate was emulsiﬁed with a mineral oil plus surfactant solution (90% w/w Sigma M1180
USP light grade mineral oil; 10% w/w Sigma M8819 mannide monoleate
surfactant), as used in GonaCon, in order to maximize the antibody
response to GnRH [38]. Treatment groups receiving three doses were
administered a prime dose followed by two boosters at 15 day intervals.
Treatment groups receiving six doses were administered a prime dose
followed by ﬁve boosters at 5 day intervals. Controls were not dosed and
were used to compare the reproductive output with that of other groups.
2.3. Analyses
Anti-GnRH antibody titres in serum samples were quantiﬁed using an
indirect ELISA technique outlined in Miller et al. [39], Levy et al. [40]
and Bender et al. [41], adapted for the laboratory rat using rabbit anti-rat
IgG, followed by goat anti-rabbit IgG conjugated with horseradish
peroxidase (Sigma Chemical Co., St. Louis, MO, USA). A post-treatment
serum sample was considered positive for anti-GnRH antibodies if the
optical density value was greater than the mean optical density plus two
standard deviations of the control (pre-treatment sample) values for each
respective dilution.
Differences in the proportions of females giving birth and litter sizes
were analysed using Fisher's exact, Mann-Whitney U, and Kruskal-Wallis
tests in SPSS for Windows (Version 25, IBM Corp., 2013). One-tailed tests
were used when the direction of the effect could be predicted, otherwise
two-tailed tests were employed. Differences in anti-GnRH antibody titre
levels between experimental groups were examined by ordinal logistic
regression using the package “MASS” [42] in R version 3.4.3 [43] (odds
ratio (OR) and their 95% conﬁdence intervals (CI) are reported). An
alpha level of 0.05 was used for all statistical tests. A receiver operating
characteristic (ROC) analysis was used to quantify how accurately the
anti-GnRH antibody titre level can be used to discriminate between two
states, "fertile" and "infertile". A ROC curve was created based on the
trade-off between sensitivity and speciﬁcity at different cut-off points (or
thresholds) of a diagnostic test with a continuous outcome (our measure
of anti-GnRH antibody titre level in a female) compared to a gold standard test (whether the female was later observed to give birth). A
sensitivity 95% was used as the criterion to derive the threshold, based
on anti-GnRH antibody titres, above which rats were predicted to be
infertile.
The study was approved in the UK by the Animal and Plant Health
Agency's Animal Welfare Ethical Review Body and carried out in accordance with the U.K. Animals (Scientiﬁc Procedures) Act 1986.
3. Results
In Trial 1, one animal in Group 4 died at the beginning of the trial
(suspected liver pathology), and another in Group 5 died for unknown
causes. In Trial 2, one animal in Group 6 died for unknown causes.
3

G. Massei et al.

Heliyon 6 (2020) e03781

MAF-IMX294 low concentration, low frequency group (Table 2, Trial 2 Group 1). This was in contrast to the results from an equivalent treatment
dose in Trial 1, where 14 out of 20 females (70%) displayed titres (Trial 1
- Groups 3 and 6, Table 2).
The highest titres in Trial 2 were observed in the IM MAF-IMX294
treatment group (Group 5), where all females (n ¼ 10) displayed tires
1024k. The inclusion of an additional mineral oil and surfactant
emulsion in the IM MAF-IMX294 formulation in Trial 2 (Group 5,
Table 2) increased the immune response compared to the IM MAFIMX294 without additional emulsion tested in Trial 1 (Groups 1 and 4,
Table 2).

3.1. Anti-GnRH antibody titres in relation to treatment
3.1.1. Trial 1
MAF-IMX294 generated anti-GnRH antibody titres detectable 45 days
after ﬁrst dosing via all three delivery routes (intramuscular injection,
nasopharyngeal lavage, and oral lavage, Table 2). These titres ranged
from 1k (i.e. maximum dilution at which antibodies were detected being
1:1,000) to 1024k. The method of MAF fragmentation did not affect the
immunogenicity of the vaccine as no signiﬁcant differences were
observed in the odds of having higher anti-GnRH antibody titres between
MAF-U and MAF-M groups (OR: 0.97 (95% CI: 0.38–2.43), p ¼ 0.94).
Consequently, data were pooled within delivery route for the analysis of
breeding success presented below: Groups 1 and 4- MAF-IMX294 intramuscular injection (IM); Groups 2 and 5- MAF-IMX294 nasopharyngeal
lavage (NP); Groups 3 and 6- MAF-IMX294 oral lavage (OL). Data from
the control groups (MAF-M only IM, NP, and OL) were also pooled as no
females in these three groups exhibited detectable anti-GnRH antibody
titres.
The GonaCon positive control treatment (Group 10), generated the
highest antibody titres (512k-2048k, Table 2). In the MAF-IMX294
treatments, 95% (18 out of 19) of rats injected with MAF-IMX294
(Group 1 and 4) had antibody titres, ranging between 4k and 1024k.
Of rats administered MAF-IMX294 via the oral (Group 3 and 6) or
nasopharyngeal (Group 2 and 5) route 70% (14 out of 20) and 53% (10
out of 19) respectively displayed titres, all 128k.
Titres generated by the IM formulations were signiﬁcantly higher
than those generated through oral treatment (OR: 26.1 (95% CI:
6.7–118.2), p < 0.001). There was no signiﬁcant difference in titre levels
of females between nasopharyngeal delivery and oral delivery groups
(OR: 0.98 (95%CI: 0.3–3.1), p ¼ 0.98).

3.2. Litter production in relation to treatment
3.2.1. Trial 1
In Trial 1, no difference in number of females producing litters
(Kruskal-Wallis, H ¼ 2, N ¼ 15, 2 d.f., P ¼ .368) or litter size (KruskalWallis, H(2) ¼ 2.81, p ¼ 0.25) was found between the three MAF only
control groups, hence these groups were pooled for further analyses. No
females from the GonaCon group (Group 10) produced litters.
The number of females that produced a litter in any of the three MAFIMX294 groups did not differ signiﬁcantly from that of the pooled control
group (Table 3, Fisher's exact two-sided; all p  0.2). For all females that
produced litters in the MAF-IMX294 groups, litter size did not differ from
that of the control group (Kruskal-Wallis, H (3) ¼ 1.81, p ¼ 0.61). These
results indicate that, regardless of delivery route, treatment with MAFIMX294 did not appear to affect fertility in this trial.
3.2.2. Trial 2
In Trial 2, the proportion of rats that produced litters in groups
administered oral MAF-IMX294 (Groups 1–4) did not differ from that of
the controls (Group 6) (Fisher's exact one-sided, p ¼ 0.43, Table 3).
However, six out of ten females in the high concentration, high frequency
group (Group 3) did not produce litters. The proportion of rats producing
litters in Group 3 (4/10) was signiﬁcantly lower than that of the other
three oral treatment groups in Trial 2 combined, where 7/10, 9/10 and
7/10 females produced litters in Groups 1, 2 and 4 respectively (Fisher's
exact one-sided, p ¼ 0.04). This was also lower than the number of females that produced litters in the negative control group (Group 6) in

3.1.2. Trial 2
In Trial 2, the oral dosing of MAF-IMX294 successfully elicited antibody titres in 17 of 40 treated females, ranging between 32k and 512k
(Table 2). Increasing the dose frequency and concentration enhanced the
treatment effect as signiﬁcantly higher titres were observed at high
concentration formulations (OR ¼ 11.6 (95% CI: 2.7–60.9), p ¼ 0.002)
and higher dose frequencies (OR ¼ 5.2 (95% CI: 1.3–24.5), p ¼ 0.02). No
anti-GnRH antibody titres were observed in the ten females from the oral

Table 2. The number of female rats with anti-GnRH antibody titres (presented as the highest 1:X,000 dilution at which antibodies were detected 45 days after ﬁrst dose
was administered in Trial 1 and Trial 2. OL ¼ Oral lavage; NP ¼ Nasopharyngeal; IM ¼ Intramuscular injection; LC ¼ Low concentration; HC ¼ High concentration; NT ¼
No titre detectable.
Trial

Group

Treatment

N

Titre (1:X,000)
NT

1

% with titre
2

4

8

16

32

64

128

256

512

1

4

1

1

2

1

2

2

2

1

2

1024

2048

1

1

IM MAF-U-IMX294

10

1

1

4

IM MAF-M-IMX294

9

0

1

2

NP MAF-U-IMX294

10

5

1

5

NP MAF-M-IMX294

9

4

1

3

OL MAF-U-IMX294

10

4

1

6

OL MAF-M-IMX294

10

2

1

10

IM GonaCon

10

0

1

7

IM MAF-M only

5

5

0

1

8

NP MAF-M only

5

5

0

1

9

OL MAF-M only

5

5

0

2

1

OL MAF-IMX294 LC x 3

10

10

2

2

OL MAF-IMX294 HC x 3

10

4

1

2

3

OL MAF-IMX294 HC x 6

10

4

1

2

4

OL MAF-IMX294 LC x 6

10

5

2

5

IM MAF-IMX294 x 3

10

0

2

6

Control

9

9

1
2
1

1

3

1

1

3

1

1

2

2

2

90
1

100
50
55.56
60

1

80
2

2

6

100

0

3

1

4
1

1

60

4

60

1

50
1

9

100
0

a) “MAF-U” and “MAF-M” groups were pooled as no differences were found in anti-GnRH antibody titres between these groups.
b) Negative control groups (MAF only - IM, OL, and NP) were merged as no differences were found in anti-GnRH antibody titres between these groups.
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Table 3. Number of female rats breeding in each group and mean litter size (plus standard deviation, SD) of females that bred in Trial 1 and Trial 2. Abbreviations as in
Table 2.
Trial

Group

Treatment

Doses

n

n bred

% bred

Mean (SD) litter size of breeding rats

1

1

IM MAF-U-IMX294

3

10

7

70

8.43 (2.77)

1

4

IM MAF-M-IMX294

3

9

7

77.8

12.71 (2.31)

1

2

NP MAF-U-IMX294

3

10

9

90

10.77 (2.66)

1

5

NP MAF-M-IMX294

3

9

7

77.8

10.29 (2.81)

1

3

OL MAF-U-IMX294

3

10

7(a)

70

11.71 (3.49)

1

6

OL MAF-M-IMX294

3

10

9

90

10.22 (4.52)

1

10

IM GonaCon

1

10

0

0

-

1

7

IM MAF-M only

3

5

5

100

9.4 (2.94)

1

8

NP MAF-M only

3

5

4

80

7 (3.24)

1

9

OL MAF-M only

3

5

5

100

10.6 (4.32)

2

1

OL MAF-IMX294 LC

3

10

7

70

9.86 (2.85)

2

2

OL MAF-IMX294 HC

3

10

9

90

9.67 (2.18)

2

3

OL MAF-IMX294 HC

6

10

4

40

9.33 (3.06)(b)

2

4

OL MAF-IMX294 LC

6

10

7

70

9.14 (3.76)

2

5

IM MAF-IMX294

3

10

0

0

0.00 (0.00)

2

6

Control

-

9

7

78

9.29 (3.64)

a)
b)

Unknown if 1 female bred.
n ¼ 3, litter size unknown for 1 female.

GnRH antibody titres greater than 1024k indicated complete infertility,
as none of the 15 rats with titres of 2048k produced litters. Titres between 256k and 1024k were associated with a reduction in the proportion of females producing litters. Of females with no titres, 76.9%
produced litters (30 out of 39), compared to 84.8% of females breeding
with titres between 1k and 128k (39 out of 46), and 17.3% of females
breeding with titres 256k (four out of 23). The difference in number of
individuals producing litters with a titre of 256k compared to females
with no titre was signiﬁcant (Fisher's exact one-sided, p < 0.001). Across
trials, there was no evidence that anti-GnRH antibody titres lower than
256k impaired fertility as there was no signiﬁcant difference found in the
proportion of MAF-IMX294 treated females producing litters between
those with no titre and those with titres between 1k and 128k (Fisher's
exact one-sided, p ¼ 0.19).
Across orally delivered treatments of MAF-IMX294 in Trial 2, seven of
the females given oral doses of MAF-IMX294 generated titres of 256k or
more and ten females exhibited titres between 32k and 128k. None of the
females with titres 256k produced litters, which was a signiﬁcantly
lower proportion than that of females with titres below this threshold, in

which two out of nine rats did not litter, although this difference was not
statistically signiﬁcant (Fisher's exact one-sided p ¼ 0.12). The lack of
signiﬁcance may have been due to small sample size. When the proportion of rats that produced litters in Group 3 (4/10) was compared to that
of the combined negative control group of Trial 1 (14/15), with a relatively larger sample size, the difference between groups was signiﬁcant
(Fisher's exact one-sided p ¼ .007).
There was no difference in litter sizes between females that produced
litters in Group 3 (high concentration, high frequency) and rats in the
negative control group (Group 6) (Table 3, Mann-Whitney U ¼ 58, p ¼
0.136).
3.3. Breeding in relation to anti-GnRH antibody titre
The ROC curve indicates that titres of 256k are highly associated
with infertility across all trials (Figure 1).
Using the threshold of 256k, the levels of producing litters in relation
to titre were examined for all rats dosed with oral and injectable formulations of MAF-IMX294 in Trial 1 and Trial 2. In 108 MAF-IMX294
treated rats, 69 animals exhibited anti-GnRH antibody titres. Anti-

% females producing a litter

n=3 n=3
100%
90%
80%
70%
60%
50%
40%
30%
20%
10%
0%

n=4 n=7
n=9

n=7

n=63

n=11
n=4

n=4
n=10
n=1
NT

1

n=15
2

4

8

16

32

64

128 256 512 1024 2048

An-GnRH anbody tre level (1:X,000)
Figure 1. Percentage of female rats that produced litters in relation to anti-GnRH antibody titre (1: X,000) across all treatment groups in Trial 1 and Trial 2. NT ¼ No
detectable titres. n ¼ sample size.
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oral routes. This suggests that the MAF-IMX294 has potential for the
formulation of an oral anti-GnRH based immunocontraceptive vaccine
for mammals. As human-wildlife conﬂicts increase, oral immunocontraceptives would represent a signiﬁcant tool to control overabundant
populations of wildlife. For some key target species, such as the wild boar
(Sus scrofa), systems are already available for the delivery of baits containing contraceptives [48]. However, before oral contraceptives can be
added to the toolbox of methods to manage wildlife, new studies will be
required to test doses and frequency of dosing for each species, to optimise bait formulation, and to evaluate the feasibility and costs of using
this method for population control.

Table 4. Mean litter size of female rats that produced litters (bred) in relation to
anti-GnRH antibody titre across all treatment groups in Trial 1 and Trial 2.
Titre (1:X,000)

N bred

Mean litter size

SD

0

51

9.72(a)

3.31

1–128

39

10.46

3.7

>128

4

9.5

1.29

Total

94

10.02

3.42

(a)

n ¼ 50, litter size unknown for one female.

which nine out of ten produced litters (Fisher's exact one-sided, p <
0.001).
For all treatments, litter size did not differ signiﬁcantly between females with no titre, those with titres of 1-128k, that did not appear to
inﬂuence the probability producing litters, and those with titres of 256k
that reduced this probability (Table 4, Kruskal-Wallis, H (2) ¼ 1.67, p ¼
0.43).
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4. Discussion
This study provided the ﬁrst evidence of anti-GnRH antibody titres
generated by oral delivery of an immunocontraceptive vaccine (Trial 1).
This represents a major breakthrough in eliciting an immune response to
a small ‘self’ hormone, like GnRH, through an oral route. Despite the
immune response, the titres induced from oral treatments in Trial 1 were
insufﬁcient to affect female fertility. However, Trial 2 indicated that
increasing both the dose concentration and the frequency of oral
administration improved the immune response. This trial provided the
ﬁrst evidence of reduced fertility arising from oral dosing with an antiGnRH immunocontraceptive vaccine. In addition, the results of both
trials suggested that anti-GnRH antibody titres of 256k are associated
with infertility in female rats.
In Trial 2, the lack of difference in litter size between the females in
Group 3 that did produce litters and the control group was likely due to
the treated females not responding to the vaccine. All four breeding females had no detectable anti-GnRH titres, indicating that their reproduction was entirely unaffected by treatment.
The absence of antibody titres in rats in the low concentration-low
frequency group (Group 1) in Trial 2 was unexpected, as an equivalent
formulation elicited immune responses in 14 out of 20 rats (Group 3 and
6) in Trial 1. This discrepancy may have been due to variation in batches
of reagents or plates and clearly limited the comparisons that could be
drawn between trials but not within trials. Although direct comparisons
between species need to be interpreted with care, the strength of the antiGnRH immune response required to affect fertility in the rat demonstrated in this study (256k or above) is higher than observed in several
other species such as white-tailed deer and feral horses, for which titres
of 64k typically impair fertility following treatment with GonaCon [27,
44].
Mathematical models have suggested that in wild rodents a minimum
of 60–70% of both sexes need to be rendered infertile for at least three
generations for fertility control to have an effect at population level [45,
46]. As the most effective oral dosing formulation in this study indicated
infertility in 60% of treated rats, the next steps will focus on exploring
methods for increasing the immunogenicity of the oral vaccine. Further
investigation should consider methods of vaccine protection through the
gastrointestinal tract. In parallel, using bioadhesive compounds could
potentially maximise vaccine uptake by providing an intimate contact
between these drugs and the mucosa, thus maintaining a high concentration at the absorptive surface for an extended period [47]. Future
studies should test dosing schedules that are effective over a timescale
commensurate with a practical baiting strategy as well as species-speciﬁc
methods to deliver contraceptives in baits.
Overall, this study demonstrated that MAF-IMX294 induced immune
responses sufﬁcient to reduce fertility in rats through both injectable and
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